Collaboration in clinical research is a phrase that gets thrown around often. It sounds good. It makes teams feel like they’re working together. But too often, what we see in practice is coexistence, not collaboration. Research units work side by side, yet their data, decisions, and goals remain disconnected. This isn’t just an internal problem. It affects patients, delays timelines, and limits what trials can achieve.
True collaboration means more than holding meetings or sharing updates. It means breaking down barriers that keep departments, teams, and external partners from working in lockstep. Without that, we’re not working together. We’re just working near each other.
One of the most persistent issues in clinical research is siloed work. Departments often develop their own systems, processes, and priorities. The regulatory team focuses on compliance. Operations manage logistics. Patient engagement teams think about recruitment. But when these groups don’t talk to each other in real time, they miss critical connections. Recruitment targets may be misaligned with regulatory timelines. Protocol changes might not be shared with patient teams soon enough. And so, small gaps become major setbacks.
This fragmented approach is called clinical trial silos and presents the following characteristics.
These silos don’t form on purpose. They come from long-standing organisational habits, legacy systems, and even cultural norms that reward individual team success over shared outcomes. But to truly collaborate, those silos need to come down.
So, what’s stopping teams from working more closely? It’s not just ego or bad communication. Research collaboration barriers are baked into the structure of how trials are set up.
The truth is, collaboration takes time. And time is something trials are always short on. There’s pressure to hit milestones, secure funding, and publish results. In that race, it can feel easier to stick with the same playbook than to slow down and build new habits. But that resistance to change is one of the biggest research collaboration barriers facing the industry today.
What’s the real cost of these clinical trial silos? We need to be honest about the impact. Siloed working leads to duplicated effort, missed opportunities, slower progress, and ultimately, can compromise the quality and speed of research outcomes. It’s not just an internal frustration; it has real-world consequences.
Collaboration won’t happen just because leadership says it matters. It needs systems that reward cross-functional input and habits that prioritise feedback. For example, a shared platform that allows patient-facing teams to comment on draft protocols in real time can prevent missteps. Including tech and operations leads early in the planning process helps flag potential risks before they grow.
Even simple shifts in meeting formats can help. Bringing together clinical, regulatory, and patient teams for a weekly sync—with a focus on decision-making, not just updates—can quickly improve alignment. The goal isn’t to make everyone do everything. It’s to make sure the people doing the work understand how it connects to others.
The first step is admitting there’s a problem. Are we just sharing a postcode, or are we genuinely working as one unit? It’s time for a hard look at how we operate.
It’s not just about how teams work internally. True collaboration also means involving external voices. That includes site staff, vendors, and most importantly, patients. A trial can only be considered collaborative if the people affected by it have had a say in shaping it.
Co-design methods, patient advisory panels, and site feasibility input can all feed into trial design in meaningful ways. These aren’t just feel-good practices. They lead to clearer protocols, stronger recruitment, and better data. Collaboration with patients can highlight what works in the real world—and what doesn’t. Ignoring those insights often leads to costly amendments and delayed enrolment.
Researchers often say they want diverse enrolment. That starts with involving diverse voices early. The more perspectives you build in from the beginning, the fewer barriers you face later.
When collaboration is done right, it shows in every part of the trial’s execution. Teams are aligned. Patients are informed. Sites are supported. Most importantly, outcomes improve.
Keith Berelowitz is the Founder of trialport, a company redefining patient engagement and retention in clinical trials using living experience, proven methods, and AI.